Inactive Instrument

Highlights AIT Therapeutics Inc Other OTC

Equities

US50027L1070

End-of-day quote Other OTC Other stock markets
- ^USD	-

30/04	Truist Lowers Price Target on Beyond Air to $8 From $10, Keeps Buy Rating	MT
12/02	Beyond Air, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Beyond Air, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	13/02	CI
Beyond Air, Inc. Provides Revenue Guidance for the Fiscal Year 2025	13/02	CI
Earnings Flash (XAIR) BEYOND AIR Posts Q3 Revenue $391,000, vs. Street Est of $0.45M	13/02	MT
Beyond Air, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	14/11	CI
Earnings Flash (XAIR) BEYOND AIR Reports Q2 Revenue $239,000, vs. Street Est of $482,000	14/11	MT
Beyond Air, Inc. Provides Revenue Guidance for the Fiscal Year Ending March 31, 2025	14/11	CI
Beyond Air, Inc. Receives Innovative Technology Contract from Vizient for LungFit PH	16/23/16	CI
EARNINGS: Andrews Sykes revenue up; Safestay optimistic	26/23/26	AN
Beyond Air, Inc. Announces Publication of Positive New Preclinical Data for the Treatment of Autism Spectrum Disorder	19/23/19	CI
Beyond Air, Inc. and Getz Healthcare Enter Strategic Collaboration to Commercialize LungFit PH in Asia-Pacific Region	07/23/07	CI
Beyond Air, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023	11/23/11	CI
Earnings Flash (XAIR) BEYOND AIR Posts Q1 Revenue $59,000, vs. Street Est of $0.34M	11/23/11	MT
Beyond Air, Inc. Announces Positive Preclinical Data on Role of Nitric Oxide in Autism Spectrum Disorder	08/23/08	CI
Beyond Air, Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	24/23/24	CI
Beyond Air, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	10/23/10	CI
Beyond Air, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	09/22/09	CI
Beyond Air® Announces Positive Data for Inhaled Nitric Oxide (NO) to Treat COVOD-19 with LungFit® PRO in A Poster Presentation At IDWeek 2022	24/22/24	CI
Beyond Air Reports 'Positive' Data From LungFit GO Trial of Nontuberculous Mycobacteria Lung Disease	18/22/18	MT
Beyond Air, Inc. Announces Positive Data from At-Home Pilot Study in Patients with Refractory NTM Lung Infection Treated with (NO) Using the LungFit® GO at the CHEST Annual Meeting 2022	18/22/18	CI
Beyond Air Announces Annals of the American Thoracic Society Published Review of the Third Pilot Study of High Dose Nitric Oxide for Bronchiolitis	03/22/03	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights AIT Therapeutics Inc Other OTC

Equities

US50027L1070

Highlights

Filters